Efficacy of a Single-Agent Ts1 (Tegafur, Gimeracil, and Oteracil) in Recurrent Gastric Cancer after Progression from Previous Oxaliplatin, Irinotecan, and Anti-Her2 Targeted Therapy: A Case Report
Abstract
Background: Gastric cancer ranks fourth globally in cancer-related deaths, with advanced cases having a median survival of less than 12 months. Timely surgery improves survival for localized cancer, but advanced and recurring cases have low survival rates. Treatment options include 5-fluorouracil (5-FU), but TS-1, a modified form of 5-FU, shows promise. Two Japanese trials found TS-1 effective in advanced gastric cancer, with response rates of 44% and 49%, and survival periods of 207 and 250 days. TS-1 has fewer adverse effects than 5-FU. This case report demonstrates TS1’s efficacy as a second-line treatment for recurrent gastric cancer post-previous therapies.
Methods: The case involves a 44-year-old Filipino woman with a 2-month history of upper GI symptoms.
Results: This case initially presented with symptoms of easy fatigability, epigastric pain, and anemia. Gastroscopy revealed gastric adenocarcinoma, leading to radical subtotal gastrectomy and adjuvant chemotherapy with Epirubicin, oxaliplatin, and capecitabine. She achieved a complete response for nine months until a left pelvoabdominal mass was discovered and surgically removed, revealing recurrent metastatic adenocarcinoma. Treatment shifted to docetaxel, irinotecan, and Trastuzumab due to HER2neu positivity, followed by maintenance therapy with Trastuzumab plus capecitabine. In December 2022, the patient experienced epigastric pain, prompting imaging revealing a stomach mass. Despite local therapy with radiation,…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.